S2L.F BAUSCH + LOMB CORP.
- Market cap
- EUR 6.76B
- P/E
- -
- P/B
- 1.18x
- ROE
- -1.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is S2L.F undervalued?
Graham numberThe Graham number of BAUSCH + LOMB CORP. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BAUSCH + LOMB CORP. fundamental analysis
No fundamental analysis for BAUSCH + LOMB CORP. yet.
BAUSCH + LOMB CORP. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BAUSCH + LOMB CORP.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are in…
Full company profileBAUSCH + LOMB CORP. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BAUSCH + LOMB CORP. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 3.77B | 4.15B | 4.79B | 5.10B | 5.35B |
| Gross Profit | 2.25B | 2.50B | 2.92B | 3.05B | 3.36B |
| Operating Income | 220M | 204M | 206M | 188M | 469M |
| EBITDA | 598M | 499M | 601M | 525M | 764M |
| Net Income | 6.00M | -260M | -317M | -360M | -70.7M |
| EPS | 0.02 | -0.74 | -0.90 | -1.02 | -0.20 |
| Balance Sheet | |||||
| Total Assets | 11.1B | 13.4B | 13.5B | 14.0B | 14.0B |
| Total Liabilities | 4.04B | 6.52B | 6.93B | 7.50B | 7.45B |
| Shareholders' Equity | 7.03B | 6.85B | 6.47B | 6.45B | 6.44B |
| Cash & Short-term Investments | 354M | 331M | 305M | 383M | 513M |
| Cash Flow | |||||
| Operating Cash Flow | 345M | -17.0M | 232M | 283M | 557M |
| Capital Expenditure | 175M | 181M | 291M | 349M | 301M |
| Free Cash Flow | 170M | -198M | -59.0M | -66.0M | 256M |
| Ratios | |||||
| ROE | 0.1% | -3.8% | -4.9% | -5.6% | -1.1% |
| ROA | 0.1% | -1.9% | -2.4% | -2.6% | -0.5% |
| Net Profit Margin | 0.2% | -6.3% | -6.6% | -7.1% | -1.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BAUSCH + LOMB CORP. dividends
BAUSCH + LOMB CORP. has not paid dividends in the last 4 fiscal years.
Who owns BAUSCH + LOMB CORP.
- Insiders 87.12%
- Institutions 11.21%
- Public & others 1.67%
- Shares outstanding 357M
- Free float 46.4M
BAUSCH + LOMB CORP. company profile
- Company name
- BAUSCH + LOMB CORP.
- Ticker
- S2L.F
- ISIN
- CA0717051076
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 13,000
- Fiscal year end
- December
- Address
- 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
- Phone
- 905 695 7700
- Website
- bausch.com
About BAUSCH + LOMB CORP.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
BAUSCH + LOMB CORP. management
10- Mr. Osama A. EldessoukyExecutive VP & CFO · born 1972
- Mr. A. Robert D. BaileyExecutive VP & Chief Legal Officer · born 1963
- Dr. Yehia Hashad M.D., Ph.D.Executive VP of Research & Development and Chief Medical officer · born 1968
- Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer · born 1976
- Mr. Thomas J. AppioInterim CEO & Chairman of the Board · born 1962
- Mr. Alan Waterhouse CPFA, MBAExecutive VP and Chief Supply Chain & Operations Officer · born 1960
- Mr. Frederick J. MunschSenior VP, Controller & Chief Accounting Officer · born 1970
- Mr. George GadkowskiVP & Head of Investor Relations & Business Insights
- Mr. Jonathon L. KellermanChief Compliance Officer
- Mr. T.J. CrawfordChief Communications Officer